Myopia
Conditions
Brief summary
The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.
Detailed description
In this retrospective interventional case series, 16 patients with myopic CNV were included. All patients were treated with 1.25 mg of intravitreal bevacizumab followed by RF-PDT (25 J/cm²), 2 days later. All patients were previously treated with IVB monotherapy and active leaking of CNV occurred 90 to 120 days after the treatment. Best-corrected visual acuity (BCVA-ETDRS), foveal thickness (FT) on optical coherence tomography (OCT), and fluorescein and indocyanine green angiographic (FA; ICG) findings were recorded. Follow-up evaluations were carried out for 12 months.
Interventions
DRUGCombination therapy IVB + rf-PDT
low-fluence photodynamic therapy combined with intravitreal bevacizumab
Sponsors
University of Campania Luigi Vanvitelli
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Myopic CNV, CNV leakage
Exclusion criteria
* CNV not associated with high myopia * No activity of CNV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA improved | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| no CNV leakage | 6 months |
Countries
Italy
Outcome results
None listed